#pfizer

#pfizer

Pfizer beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected. The stock gapped up roughly 12.6% in pre-market trading, reflecting strong investor validation of both the beat and the company's reaffirmed full-year guidance paired with a raised EPS outlook. Management reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion but raised EPS guidance to $3.00 to $3.15 from prior guidance.

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood ( NASDAQ:HOOD ) and Fidelity. Now, it no longer takes a lot of money to make money on Wall Street, as investors can buy fractional shares with as little as $5 or $10. That opens doors for everyday people to build portfolios without needing thousands upfront. But that doesn't mean buying cheap stocks is always a good idea, since a low price could signal company problems - and certainly steer clear of penny stocks, which carry high risks of fraud and volatility. Sometimes, though, a low share price signals real opportunity.

Pfizer is the first big pharmaceutical company to reach an agreement with the Trump administration over most-favored nation drug pricing, a deal that lowers U.S. prices of certain medications and makes them available directly to patients through new online channels. The agreement announced Tuesday also gives Pfizer a grace period before facing potential tariffs on its drugs. With most-favored nation pricing, the prices of a drug in the U.S. will be matched to the lowest price of the same drug in a comparable developed nation.

Pfizer's Covid vaccine for young children may not be renewed by the FDA this fall, leading to a gap in available vaccines for those under five.

Part of moving biddable marketing channels in-house is having a deeper understanding of the brand. At an agency, the focus can often be diluted across various clients.

HII Mission Technologies earns approximately $4.5 billion annually, accounting for 1% of all DoD contract spending by developing unmanned underwater vehicles and drones for naval missions.

Pfizer's stocks have struggled in 2025, down 23% from their yearly high, despite exceeding EPS expectations but falling short in revenue due to COVID product sales decline.